The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 12,322.00
Ask: 12,324.00
Change: -108.00 (-0.87%)
Spread: 2.00 (0.016%)
Open: 12,334.00
High: 12,362.00
Low: 12,250.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks In Green On Astra Vaccine, Brexit Deal News

Wed, 30th Dec 2020 08:48

(Alliance News) - London stock prices got off to a positive start on Wednesday after the Oxford-AstraZeneca vaccine for Covid-19 got the green light from UK regulators.

The FTSE 100 index was up 10.16 points, or 0.2%, at 6,612.81 early Wednesday. The FTSE 250 index was up 44.10 points, also 0.2%, 20,941.69. The AIM All-Share index was up 0.2% at 1,152.41.

The Cboe UK 100 index was down 0.1% at 657.36. The Cboe 250 was up 0.1% at 18,312.99, and the Cboe Small Companies up 0.1% at 11,761.07.

In mainland Europe, the CAC 40 in Paris was down 0.1% while the DAX 30 in Frankfurt was flat early Wednesday.

"European stocks are trading flat on the second-to-last trading day of this year. Investors seem to be less enthusiastic about the Brexit trade deal today. However, this isn't to say that they aren't optimistic any more," said Avatrade Chief Market Analyst Naeem Aslam.

The UK and EU will on Wednesday sign a mammoth trade pact to put the seal on their drawn-out Brexit divorce in the dwindling hours before they part ways definitively at the dawning of 2021.

EU chiefs Ursula von der Leyen and Charles Michel will ink the 1,246-page Trade & Cooperation Agreement at 0830 GMT, officials in Brussels said, days after it was clinched on Christmas Eve following months of hard-fought talks.

The hefty document will then be flown by the Royal Air Force to London for UK Prime Minister Boris Johnson to add his signature, as the UK parliament embarks on a rushed debate to clear the decks before a December 31 deadline.

According to Downing Street, Johnson will tell MPs that the agreement heralds "a new relationship between Britain and the EU as sovereign equals, joined by friendship, commerce, history, interests and values".

The government only released the accompanying UK legislation on Tuesday afternoon – less than 24 hours before the debate is to start in Parliament an hour after the signing in Brussels.

Sterling was quoted at USD1.3540 early Wednesday, up from USD1.3509 at the London equities close on Tuesday. The euro traded at USD1.2259 early Wednesday, firming from USD1.2246 late Tuesday.

More areas in England will be placed under the country's toughest coronavirus restrictions, Health Secretary Matt Hancock is expected to tell the Commons on Wednesday.

Pressure mounted on the government to act as hospitals across England warned of increasing strains on services due to Covid-19 patient numbers, which have reached their highest levels during the pandemic, while 51,135 further cases and 414 deaths were reported on Tuesday.

Johnson chaired a meeting of the government's Covid-19 Operations committee on Tuesday evening, when changes to the tier system were discussed.

With case rates rising in all regions of England, as well as the number of Covid-19 patients in hospitals, any review is likely to involve areas moving up a tier rather than down.

Areas that may be moved from Tier 3 to Tier 4 due to increasing case rates include parts of the East Midlands, such as Northamptonshire and Leicestershire, as well as all areas of the West Midlands metropolitan county.

Hartlepool in north-east England, along with a handful of areas in Lancashire – Blackburn with Darwen, Burnley, Pendle and Ribble Valley – could also be upgraded from Tier 3 to 4.

More positively, AstraZeneca said its Covid-19 vaccine has been approved for emergency supply in the UK, with the first doses being released on Wednesday so that vaccinations may begin early in the New Year.

FTSE 100-listed Astra shares were up 1.1% in the morning trading on Wednesday.

The pharmaceutical firm said it aims to supply millions of doses in the first quarter as part of an agreement with the UK government to supply up to 100 million doses in total.

The vaccine was authorised by the UK Medicines & Healthcare Products Regulatory Agency, recommending two doses administered with an interval of between four and 12 weeks. Clinical trials showed the vaccine to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose.

The first doses will be released Wednesday in order for vaccinations to start early in the new year, Astra said.

The vaccine has been approved for the immunization of people aged 18 and over, with the authorisation recommending two doses administered with an interval of four to 12 weeks.

Among London mid-caps, Energean was up 0.7% after reaching an agreement with Kerogen Investments, an affiliate of Kerogen Capital, for the acquisition of Kerogen's 30% shareholding in Energean Israel. This will result in Energean owning 100% of the Israeli business.

A total consideration of between USD380 million and USD405 million, the Mediterranean-focus gas exploration and production company said.

Energean said the acquisition adds 2P reserves of 29.5 billion cubic metres of gas and 30 million barrels of liquids, representing 219 million barrels of oil equivalent in total, to the company.

Taking a 100% interest in Energean Israel will enable Energean to fully control its capital structure, it said, enhancing its ability to maximise total shareholder returns.

Elsewhere, iEnergizer jumped 12% after entering into a credit agreement for a new five-year senior secured term loan facility for USD165 million.

The IT service management company said it intends to utilise the additional financing now available to return cash to shareholders.

In Asia on Wednesday, the Japanese Nikkei 225 index closed down 0.5%. Against the yen, the dollar was quoted at JPY103.34, slightly down from JPY103.51.

In China, the Shanghai Composite closed up 1.1%, while the Hang Seng index in Hong Kong closed up 2.2%. The S&P/ASX 200 in Sydney closed down 0.3%.

Gold was quoted at USD1,878.51 an ounce early Wednesday, slightly lower than USD1,882.29 on Tuesday. Brent oil was trading at USD51.48 a barrel early Wednesday, firm from USD51.16 late Tuesday.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.